Catalog No.
EHC41801
Expression system
Mammalian Cells
Species
Homo sapiens (Human)
Protein length
Met1-Pro180
Predicted molecular weight
19.89 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
P09564
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
GP40, CD7, T-cell surface antigen Leu-9, T-cell leukemia antigen, TP41, T-cell antigen CD7
Case Report: Flow cytometric differential diagnosis of a peripheral T-cell lymphoma, NOS with complete loss of CD45 and dim expression of CD3., PMID:40510503
Engineered CRO-CD7 CAR-NK cells derived from pluripotent stem cells avoid fratricide and efficiently suppress human T-cell malignancies., PMID:40390054
SOHO State of the Art Updates and Next Questions | CD7 CAR-T Therapy for Treating CD7-Positive Hematological Malignancies: Clinical Advances and Future Directions., PMID:40374439
Verification of biological markers of subacute cutaneous lupus erythematosus via TMT labelling proteomics combined with transcriptome data., PMID:40323689
CD7-Targeted Cytotoxic Potency of Diphtheria Toxin- and Ricin-Based Immunotoxins in Targeted Therapy for T-Cell Acute Lymphoblastic Leukemia., PMID:40317108
Clinical Outcomes of CD7 CAR-T Cell Therapy in Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients., PMID:40227107
Mitochondrial uncoupler BAM15 enhances the function of CD7CAR-TCD7- cells and reduces the release of cytokines for the therapy of T-cell malignancies., PMID:40215779
Case report: The case of T-cell acute lymphoblastic leukemia treated with chemotherapy followed by anti-CD7 CAR-T cells using retroviral vector., PMID:39877371
Prognosis of aggressive adult T-cell leukemia/lymphoma with central nervous system infiltration and utility of CD7 versus CADM1 flowcytometric plots of cerebrospinal fluid., PMID:39789333
Combination of triciribine and p38 MAPK inhibitor PD169316 enhances the differentiation effect on myeloid leukemia cells., PMID:39739720
Characterisation and hierarchy of the spermatogonial stem cell compartment in human spermatogenesis by spectral cytometry using a 16-colors panel., PMID:39725808
Differentiating reactive and neoplastic gamma-delta (γδ) T-cell expansions in the peripheral blood and bone marrow., PMID:39721945
Clinical outcomes and safety of CAR-T cells in treatment of T-Cell acute lymphoblastic leukemia/lymphoma., PMID:39692783
CD7-targeting pro-apoptotic extracellular vesicles: A novel approach for T-cell haematological malignancy therapy., PMID:39676736
Case report: CD7-targeted autologous CAR-T therapy for the treatment of T-cell acute lymphoblastic leukemia undergoing allogeneic peripheral blood stem cell transplantation in the long-term follow-up., PMID:39620223
Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia., PMID:39561281
Naturally selected CD7-directed CAR-T bridging allo-HSCT in refractory acute myeloid leukemia: a case report and review., PMID:39469704
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial., PMID:39354195
Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trial., PMID:39244642
Blast phase of chronic myeloid leukemia presenting as early T-cell precursor acute lymphoblastic leukemia., PMID:39235991
Implicit Flow Cytometric Diagnosis of Classic Hodgkin Lymphoma Using CD3+CD4+CD26- T-Cells., PMID:39235202
Fratricide-resistant CD7-CAR T cells in T-ALL., PMID:39227445
Evaluation of Sézary cell marker expression and cell death behaviour upon in vitro treatment by flow cytometry in Sézary syndrome patients., PMID:39219147
Pharmacologic HIF stabilization activates costimulatory receptor expression to increase antitumor efficacy of adoptive T cell therapy., PMID:39196939
Clinical Efficacy and Safety of CD7-Targeted CAR T Cell Therapy for T-cell Malignancies: A Systematic Review and Meta-analysis., PMID:39192642
[CAR T-cell therapy for T cell malignancies: challenges and recent advances]., PMID:39098015
[Current state and future prospects of CAR T-cell therapy for myeloid malignancies]., PMID:39098014
Quantification of the median fluorescence intensity of CD3 and CD4 in mycosis fungoides/Sezary syndrome versus non-neoplastic control cases in peripheral blood., PMID:39093388
The significance of T-BET-positive CD8 T-cells with diminished CD5 expression in Kikuchi-Fujimoto disease., PMID:39085130
Acute myeloid leukemia with ETV6::CHIC2 fusion gene: 'Pitfalls' in diagnosis., PMID:39037342
Clinicopathologic features and outcomes of acute leukemia harboring PICALM::MLLT10 fusion., PMID:38971327
CAR-T cell therapy in AML: recent progress and future perspectives., PMID:38963636
CD7 CAR T-Cell Therapy and Allogeneic HSCT. Reply., PMID:38959487
CD7 CAR T-Cell Therapy and Allogeneic HSCT., PMID:38959486
CD7 CAR T-Cell Therapy and Allogeneic HSCT., PMID:38959485
Intraoral CD30+ T-Cell Lymphoproliferative Disorder with Lymphomatoid Papulosis Type C Features Mimics Lymphoma Histopathologically and Immunohistochemically., PMID:38941041
Thyroid autoimmunity in different phenotypes of polycystic ovary syndrome: a single-center experience., PMID:38850509
Chimeric antigen receptor T-cell therapy for T-cell acute lymphoblastic leukemia., PMID:38832423
Mycosis fungoides refractory to treatment - importance of a multidisciplinary approach., PMID:38822949
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study., PMID:38821940
Flow cytometric profiles with CD7 and CADM1 in CD4+ T cells are promising indicators for prognosis of aggressive ATL., PMID:38820467
IL-15 gene mutation as a molecular risk factor in acute lymphoid leukemia., PMID:38814240
Integrative immunophenotypic and genetic characterization of acute myeloid leukemia with CBFB rearrangement., PMID:38801226
Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37+ lymphoid malignancies., PMID:38781564
Case report: Preventive infusion of donor-derived CD7 chimeric antigen receptor T cells after allogeneic hematopoietic stem cell transplantation., PMID:38745670
InsT-ALLing CD7 chimeric antigen receptors before transplantation., PMID:38676290
Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis., PMID:38657244
A safety and efficacy study of allogeneic haematopoietic stem cell transplantation for refractory and relapsed T-cell acute lymphoblastic leukaemia/lymphoblastic lymphoma patients who achieved complete remission after autologous CD7 chimeric antigen receptor T-cell therapy., PMID:38613241
Terminal deoxynucleotidyl transferase expression in different subtypes of childhood B-cell acute lymphoblastic leukemia., PMID:38579576
The role of quiescent thymic progenitors in TAL/LMO2-induced T-ALL chemotolerance., PMID:38553571
For research use only. Not for human or drug use.
